Acharya Abhinav P, Clare-Salzler Michael J, Keselowsky Benjamin G
Materials Science and Engineering, University of Florida, 130 BME/PO Box 116131, Gainesville, FL 32611-6131, USA.
Biomaterials. 2009 Sep;30(25):4168-77. doi: 10.1016/j.biomaterials.2009.04.032. Epub 2009 May 28.
Immunogenomic approaches combined with advances in adjuvant immunology are guiding progress toward rational design of vaccines. Furthermore, drug delivery platforms (e.g., synthetic particles) are demonstrating promise for increasing vaccine efficacy. Currently there are scores of known antigenic epitopes and adjuvants, and numerous synthetic delivery systems accessible for formulation of vaccines for various applications. However, the lack of an efficient means to test immune cell responses to the abundant combinations available represents a significant blockade on the development of new vaccines. In order to overcome this barrier, we report fabrication of a new class of microarray consisting of antigen/adjuvant-loadable poly(D,L lactide-co-glycolide) microparticles (PLGA MPs), identified as a promising carrier for immunotherapeutics, which are co-localized with dendritic cells (DCs), key regulators of the immune system and prime targets for vaccines. The intention is to utilize this high-throughput platform to optimize particle-based vaccines designed to target DCs in vivo for immune system-related disorders, such as autoimmune diseases, cancer and infection. Fabrication of DC/MP arrays leverages the use of standard contact printing miniarraying equipment in conjunction with surface modification to achieve co-localization of particles/cells on isolated islands while providing background non-adhesive surfaces to prevent off-island cell migration. We optimized MP overspotting pin diameter, accounting for alignment error, to allow construction of large, high-fidelity arrays. Reproducible, quantitative delivery of as few as 16+/-2 MPs per spot was demonstrated and two-component MP dosing arrays were constructed, achieving MP delivery which was independent of formulation, with minimal cross-contamination. Furthermore, quantification of spotted, surface-adsorbed MP degradation was demonstrated, potentially useful for optimizing MP release properties. Finally, we demonstrate DC co-localization with PLGA MPs on isolated islands and that DCs do not migrate between islands for up to 24 h. Using this platform, we intend to analyze modulation of DC function by providing multi-parameter combinatorial cues in the form of proteins, peptides and other immuno-modulatory molecules encapsulated in or tethered on MPs. Critically, the miniaturization attained enables high-throughput investigation of rare cell populations by reducing the requirement for cells and reagents by many-fold, facilitating advances in personalized vaccines which target DCs in vivo.
免疫基因组学方法与佐剂免疫学的进展相结合,正引领着疫苗合理设计的发展进程。此外,药物递送平台(如合成颗粒)在提高疫苗效力方面显示出前景。目前,有大量已知的抗原表位和佐剂,以及众多可用于制备各种用途疫苗的合成递送系统。然而,缺乏一种有效的方法来测试免疫细胞对大量可用组合的反应,这对新疫苗的开发构成了重大障碍。为了克服这一障碍,我们报告了一种新型微阵列的制备,该微阵列由可负载抗原/佐剂的聚(D,L-丙交酯-共-乙交酯)微粒(PLGA MPs)组成,PLGA MPs被认为是免疫治疗的一种有前景的载体,它们与树突状细胞(DCs)共定位,树突状细胞是免疫系统的关键调节因子,也是疫苗的主要靶点。目的是利用这个高通量平台优化基于颗粒的疫苗,这类疫苗旨在体内靶向DCs,用于治疗与免疫系统相关的疾病,如自身免疫性疾病、癌症和感染。DC/MP阵列的制备利用了标准的接触式印刷微阵列设备,并结合表面修饰,以实现颗粒/细胞在孤立岛屿上的共定位,同时提供背景非粘性表面以防止岛外细胞迁移。我们优化了MP过量点样针的直径,考虑到对准误差,以允许构建大型、高保真阵列。展示了每个点可重复、定量递送低至16±2个MP,并构建了双组分MP剂量阵列,实现了与制剂无关的MP递送,交叉污染最小。此外,还展示了对斑点状、表面吸附的MP降解的定量,这可能有助于优化MP的释放特性。最后,我们证明了DC与PLGA MPs在孤立岛屿上的共定位,并且DCs在长达24小时内不会在岛屿之间迁移。利用这个平台,我们打算通过以封装在MPs中或连接在MPs上的蛋白质、肽和其他免疫调节分子的形式提供多参数组合线索,来分析DC功能的调节。至关重要的是,通过将细胞和试剂的需求降低许多倍,所实现的小型化使得能够对稀有细胞群体进行高通量研究,促进了体内靶向DCs的个性化疫苗的发展。